Skip to main
  1. Stocks
  2. Acumen Pharmaceuticals
  3. Forecast
ABOS

Acumen Pharmaceuticals (ABOS) Stock Forecast & Price Target

Acumen Pharmaceuticals (ABOS) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Acumen Pharmaceuticals is viewed favorably because its ACU193-based strategy targets amyloid-beta oligomers, the toxic species thought to drive neuronal injury in Alzheimer’s disease, while avoiding heavier plaque binding that has been linked to higher ARIA risk. The ALTITUDE-AD readout and prior P1 testing support the possibility of a meaningfully cleaner safety profile, with only one symptomatic ARIA-E case reported and preclinical data suggesting 14X–40X higher brain uptake from the TfR-shuttle approach without a clear anemia signal. Fundamentally, the company’s differentiated BBB-crossing platform, on-track mid-2027 IND filing, and the market opportunity implied by a 45% PoS with 2031 market entry and 15% peak penetration underpin the bullish outlook.

Bears say

Acumen Pharmaceuticals is viewed pessimistically because ALTITUDE-AD failed to show that removing amyloid-related pathology translated into cognitive benefit, undermining the core scientific rationale for ACU193 and raising doubts that the company’s shuttle approach can overcome the biology of Alzheimer’s disease. Financially, the company posted an operating loss of $25.8M and a net loss of $25.4M in 3Q26, with $78.6M of cash, cash equivalents, and marketable securities at September 30, 2026, implying a runway only into early 2027 before the program was stopped. With the lead asset derailed, the remaining value appears limited to cash and optionality around licensing or a restart, while regulatory, safety, and execution risks remain elevated.

Acumen Pharmaceuticals (ABOS) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acumen Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Acumen Pharmaceuticals (ABOS) Analyst Forecast & Price Prediction

Get the latest Acumen Pharmaceuticals (ABOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Acumen Pharmaceuticals (ABOS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acumen Pharmaceuticals (ABOS) Forecast

Analysts have given Acumen Pharmaceuticals (ABOS) a Buy based on their latest research and market trends.

According to 2 analysts, Acumen Pharmaceuticals (ABOS) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acumen Pharmaceuticals (ABOS)


Acumen Pharmaceuticals (ABOS) Analyst Forecast & Price Prediction

Get the latest Acumen Pharmaceuticals (ABOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Acumen Pharmaceuticals (ABOS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABOS stock data and trends